March 30 (Reuters) -
ELEVAR THERAPEUTICS ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR LIRAFUGRATINIB AS SECOND-LINE CHOLANGIOCARCINOMA TREATMENT
ELEVAR THERAPEUTICS: FDA GRANTED PRIORITY REVIEW, WITH A PDUFA TARGET ACTION DATE OF SEPTEMBER 27, 2026
Further company coverage: [ ]